IND Swift Limited — Pioglitazone Exporter Profile
Indian Pharmaceutical Exporter · #7 for Pioglitazone · $1.2M export value · DGFT Verified
IND Swift Limited is the #7 Indian exporter of Pioglitazone with $1.2M in export value and 55 verified shipments. IND Swift Limited holds a 3.3% market share in Pioglitazone exports across 8 countries. The company exports 13 pharmaceutical products worth $36.7M across 9 therapeutic categories.
IND Swift Limited — Pioglitazone Export Profile: Buyers & Destinations
Where Does IND Swift Limited Export Pioglitazone?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED ARAB EMIRATES | $422.6K | 15 | 41.1% |
| QATAR | $408.7K | 12 | 39.7% |
| AUSTRALIA | $134.1K | 9 | 13.0% |
| HONG KONG | $26.1K | 10 | 2.5% |
| PHILIPPINES | $22.6K | 3 | 2.2% |
| OMAN | $6.0K | 2 | 0.6% |
| MALAYSIA | $4.8K | 2 | 0.5% |
| JAMAICA | $4.1K | 2 | 0.4% |
IND Swift Limited exports Pioglitazone to 8 countries. The largest destination is UNITED ARAB EMIRATES accounting for 41.1% of IND Swift Limited's Pioglitazone shipments, followed by QATAR (39.7%) and AUSTRALIA (13.0%). These destinations reflect IND Swift Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Pioglitazone from IND Swift Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| NEW COUNTRY HEALTHCARE LLC | UNITED ARAB EMIRATES | $357.0K | 8 |
| WELL CARE TRADING W.L.L | QATAR | $307.7K | 8 |
| WELL CARE TRADING W L L | QATAR | $70.4K | 3 |
| APOTEX PTY LTD | AUSTRALIA | $68.9K | 5 |
| LIFE PHARMA FZE | UNITED ARAB EMIRATES | $65.6K | 7 |
| APOTEX PTY LTD. | AUSTRALIA | $53.2K | 3 |
| WELL CARE TRADING | QATAR | $30.7K | 1 |
| MEDINOVA PHARMACEUTICAL INC. | PHILIPPINES | $18.9K | 2 |
| CHAMPION HEALTHCARE LTD. | HONG KONG | $17.8K | 4 |
| APOTEX PTY LIMITED | AUSTRALIA | $12.0K | 1 |
IND Swift Limited supplies Pioglitazone to 15 buyers globally. The largest buyer is NEW COUNTRY HEALTHCARE LLC (UNITED ARAB EMIRATES), followed by WELL CARE TRADING W.L.L (QATAR) and WELL CARE TRADING W L L (QATAR). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Pioglitazone Export Value and How Much Does IND Swift Limited Contribute?
India exported $35.2M worth of Pioglitazone through 2,674 shipments from 115 suppliers to 70 countries, serving 293 buyers globally. IND Swift Limited contributes $1.2M to this total, accounting for 3.3% of India's Pioglitazone exports. IND Swift Limited ships Pioglitazone to 8 countries through 15 buyers.
What Is the Average Shipment Value for IND Swift Limited's Pioglitazone Exports?
IND Swift Limited's average Pioglitazone shipment value is $22.2K per consignment, based on 55 shipments totaling $1.2M. The largest destination is UNITED ARAB EMIRATES (41.1% of IND Swift Limited's Pioglitazone exports).
How Does IND Swift Limited Compare to Other Indian Pioglitazone Exporters?
IND Swift Limited ranks #7 among 115 Indian Pioglitazone exporters with a 3.3% market share. The top 3 exporters are AUROBINDO PHARMA LTD ($15.2M), AUROBINDO PHARMA LIMITED ($4.0M), INTAS PHARMACEUTICALS LIMITED ($3.4M). IND Swift Limited processed 55 shipments to 8 destination countries.
What Pioglitazone Formulations Does IND Swift Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| GLIT 30MG (PIOGLITAZONE TABLETS USP 30MG | $150.0K | 3 |
| GLIT 15MG (PIOGLITAZONE TABLETS USP 15MG | $100.0K | 2 |
| APOTEX PIOGLITAZONE 45 MG,(Pioglitazone | $53.2K | 3 |
| GLIT 15 (PIOGLITAZONE TABLETS- 15 MG) BATCH NO: ASW10125,ASW10225, MFG: JAN2025EXP: DEC2027 | $52.9K | 2 |
| GLIT 30MG(PIOGLITAZONE TABLETS USP 30 MG | $50.0K | 1 |
| GLIT 30MG(Pioglitazone Tablets-30mg),BT# | $50.0K | 1 |
| GLIT 15MG,(Pioglitazone Tablets-15mg),BT | $50.0K | 1 |
| GLIT 30 MG(PIOGLITAZONE TABLETS-30MG)7168X2X14T BATCH NO.: WH10124 MFG: JAN 2024EXP: DEC 2026 | $50.0K | 1 |
| GLIT 15MG(PIOGLITAZONE TABLETS USP 15 MG | $45.2K | 1 |
| GLIT 15 MG(PIOGLITAZONE TABLETS-15MG)7296X2X14T BATCH NO.: WG10124 MFG: JAN 2024EXP: DEC 2026 | $40.7K | 1 |
IND Swift Limited exports 45 distinct Pioglitazone formulations including tablets, capsules, syrups, and combination drugs. The top formulation is GLIT 30MG (PIOGLITAZONE TABLETS USP 30MG with 3 shipments worth $150.0K.
Regulatory Requirements: Exporting Pioglitazone to Key Markets
What IND Swift Limited must comply with to export Pioglitazone to its top destination countries
Australia — TGA
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does IND Swift Limited Compare to Nearest Pioglitazone Exporters?
Exporters ranked immediately above and below #7 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 5 | AJANTA PHARMA LIMITED | $1.8M | 36 | 2 | $48.9K |
| 6 | MICRO LABS LIMITED | $1.6M | 98 | 9 | $15.9K |
| 7 | IND SWIFT LIMITED ★ | $1.2M | 55 | 8 | $22.2K |
| 8 | MACLEODS PHARMACEUTICALS LIMITED | $1.2M | 106 | 1 | $11.5K |
| 9 | ARISTO PHARMACEUTICALS PRIVATE LIMITED | $721.0K | 100 | 6 | $7.2K |
IND Swift Limited ranks #7 among 115 Indian Pioglitazone exporters. Average shipment value of $22.2K compared to the market average of $305.7K. The closest competitors by value are AJANTA PHARMA LIMITED and MICRO LABS LIMITED.
Which Indian Ports Ship Pioglitazone Exports?
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR | 249 | 9.3% |
| HYDERABAD ICD | 229 | 8.6% |
| DELHI AIR CARGO ACC (INDEL4) | 206 | 7.7% |
| SAHAR AIR | 205 | 7.7% |
| HYDERABAD ICD (INSNF6) | 203 | 7.6% |
| SAHAR AIR CARGO ACC (INBOM4) | 143 | 5.3% |
| MUNDRA SEA | 127 | 4.7% |
| CMA CGM LOGISTICS PARK ICD | 126 | 4.7% |
Geopolitical & Trade Policy Impact on IND Swift Limited's Pioglitazone Exports
Ind-Swift Laboratories' export operations have been influenced by recent geopolitical developments. The Israel-Iran conflict has heightened security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and increased freight rates by 40–50% on key India–Europe routes, impacting the company's logistics and cost structures. (livemint.com)
Conversely, the India–European Union Free Trade Agreement (India–EU FTA), concluded in January 2026, is poised to benefit Indian pharmaceutical exporters. The agreement eliminates tariffs on most European pharmaceutical imports, enhancing the competitiveness of Indian products in the EU market. This development presents an opportunity for Ind-Swift Laboratories to expand its footprint in Europe. (en.wikipedia.org)
In the United States, the reshoring of pharmaceutical manufacturing and potential imposition of tariffs on imports pose challenges for Indian exporters. While there are currently no import duties on Indian pharmaceutical products entering the US, the introduction of tariffs could affect the profitability of low-margin generic drugs, potentially leading to market exits. (cfo.economictimes.indiatimes.com)
IND Swift Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards remains paramount for Indian pharmaceutical exporters. Ind-Swift Laboratories has demonstrated a commitment to quality by adhering to Good Manufacturing Practices (GMP) as stipulated by the US FDA, WHO, and EU authorities. The company's manufacturing facilities in Punjab and Jammu have been inspected and approved by these regulatory bodies, facilitating access to regulated markets.
The evolving regulatory landscape, including the EU's Falsified Medicines Directive, necessitates continuous investment in quality systems and supply chain transparency. Ind-Swift Laboratories' focus on high-margin formulations underscores the importance of maintaining stringent quality standards to meet global regulatory requirements and sustain market access.
About IND Swift Limited
IND Swift Limited exports 13 products worth $36.7M. Beyond Pioglitazone, top products include Fexofenadine, Ramipril, Clarithromycin, Loratadine, Ezetimibe. View the complete IND Swift Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Pioglitazone — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Pioglitazone shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: IND Swift Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 55 individual customs records matching IND Swift Limited exporting Pioglitazone, covering 45 formulations to 8 countries via 15 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 70+ countries, 293+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Pioglitazone Export Data from IND Swift Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for IND Swift Limited's Pioglitazone exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
IND Swift Limited
Full Company Profile →
13 products · $36.7M total trade · 9 categories
Pioglitazone Stats
Company Overview
Top Products by IND Swift Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for IND Swift Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Pioglitazone. For current shipment-level data, contact TransData Nexus.